# Senzime > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/senzime). ## Overview Senzime is a global medical technology company specializing in algorithm-based patient monitoring systems aimed at reducing anesthesia-related complications. The company's flagship product, the TetraGraph system, is used in thousands of operating rooms worldwide to provide precision-based monitoring during and after surgery. Senzime collaborates with leading academic institutions and operates in over 30 markets, with subsidiaries in the US and Germany. The company is listed on the Nasdaq Main Market Stockholm and is recognized for its rapid growth and innovation in medical technology. ## Products & services • TetraGraph system for neuromuscular monitoring • EMGINE™ Sirius software for TetraGraph • Disposable sensors for patient monitoring • Licensing and distribution partnerships • Algorithm-based monitoring systems - **Neuromuscular Monitoring Systems** (50%) — Includes TetraGraph systems for precision-based patient monitoring. - **Software Solutions** (20%) — Includes EMGINE™ Sirius software for enhanced monitoring capabilities. - **Disposable Sensors** (20%) — Single-use sensors for patient monitoring during surgeries. - **Licensing and Partnerships** (10%) — Revenue from licensing and distribution agreements. - TetraGraph system for neuromuscular monitoring - EMGINE™ Sirius software for TetraGraph - Disposable sensors for patient monitoring - Licensing and distribution partnerships - Algorithm-based monitoring systems ## Customers Senzime's customers primarily include hospitals and healthcare institutions that require advanced patient monitoring solutions. The company's products are designed to improve surgical outcomes by providing real-time data on neuromuscular function, which is critical for anesthesiologists. Senzime collaborates with leading academic medical centers, such as Mayo Clinic and Harvard, to ensure its systems meet the latest clinical guidelines. The company also targets international markets through partnerships and subsidiaries, expanding its reach to over 30 countries. - **Hospitals** (primary) — Purchase TetraGraph systems for precision-based monitoring to improve surgical outcomes. - **Academic Medical Centers** (secondary) — Collaborate on research and use systems to meet clinical guidelines. - **International Distributors** (emerging) — License and distribute Senzime products in various regions. - Hospitals seeking advanced patient monitoring solutions - Healthcare institutions focused on improving surgical outcomes - Anesthesiologists requiring real-time neuromuscular data - Academic medical centers collaborating on clinical research - International markets accessed through partnerships ## Geography Senzime operates globally, with commercial activities in over 30 markets. The company has subsidiaries in the US and Germany, which are key markets for its growth strategy. Senzime's products are distributed through licensing and partnerships in other regions, allowing it to expand its international presence. The company's operations are not affected by geopolitical tensions in regions like Russia and the Middle East, as it has no direct business in these areas. - Global operations in over 30 markets - Key subsidiaries in the US and Germany - Licensing and distribution partnerships in various regions - No operations in geopolitically sensitive areas like Russia ## Strategy Senzime's strategic priorities include accelerating growth and achieving profitability by 2026. The company focuses on expanding its market presence through strategic partnerships and increasing sales of its TetraGraph systems. Senzime aims to enhance its product offerings with continuous innovation and development of new software solutions. The company also seeks to optimize its financial resources to support long-term strategic initiatives and maintain a stable cost structure. - **Accelerate growth** (medium-term) — To surpass revenue milestones and strengthen market position. - **Achieve profitability** (long-term) — To ensure sustainable financial performance. - **Product innovation** (short-term) — To maintain competitive edge and meet clinical needs. - Accelerate growth and achieve profitability by 2026 - Expand market presence through strategic partnerships - Increase sales of TetraGraph systems - Enhance product offerings with continuous innovation - Optimize financial resources for long-term initiatives ## Risks Senzime faces several risks, including financial and operational challenges. The introduction of new US tariffs poses a significant uncertainty, potentially impacting gross margins. Currency fluctuations, particularly the stronger Swedish krona, can negatively affect sales. The company also needs to manage its financial resources carefully to support growth initiatives. Additionally, as a medical technology company, Senzime must navigate regulatory changes and ensure compliance with clinical guidelines. - **US tariffs** [high] — Increase in costs affecting gross margins. - **Currency fluctuations** [medium] — Stronger Swedish krona negatively impacts sales. - **Regulatory changes** [medium] — Need to comply with evolving clinical guidelines. - New US tariffs impacting gross margins - Currency fluctuations affecting sales - Need for careful financial resource management - Regulatory changes in medical technology - Compliance with clinical guidelines ## Accounting Senzime's financial reporting is influenced by several critical accounting matters. The company has adjusted its recognition of currency effects, which now impacts net financial items rather than operating expenses. This change affects comparability with previous years. Additionally, Senzime's financial performance is subject to fluctuations due to currency exchange rates, which can impact reported sales and margins. The company also uses alternative performance measures, such as gross margin excluding amortization, to provide clearer insights into its financial health. - **Currency effects recognition** - **Alternative performance measures** - Change in recognition of currency effects impacting net financial items - Currency exchange rates affecting reported sales and margins - Use of alternative performance measures like gross margin excluding amortization - Impact of currency fluctuations on financial comparability --- *Last updated: 2026-08-11T04:04:55.744428+00:00*